A new post-grant review, PGR2026-00072, has been filed at the Patent Trial and Appeal Board involving Anagen LLC. The petition was filed on September 1, 2026, opening what could become an important proceeding for patent owners, challengers, and counsel tracking how recently issued patents are tested at the PTAB.
At this stage, the docket information publicly identifies the matter by the title Anagen LLC, but practitioners should note that early PTAB dockets do not always immediately reveal the full contours of the dispute from the caption alone. As the record develops, key documents will clarify the specific patent claims under challenge, the petitioner, the real parties in interest, and the precise statutory grounds asserted. That makes this the kind of case worth monitoring from the outset.
Because this is a post-grant review, the challenged patent is necessarily one that falls within the PGR framework, which allows broader attacks than inter partes review. Unlike IPR, a PGR petition can raise not only anticipation and obviousness issues under Sections 102 and 103, but also patent-eligibility, written description, enablement, and indefiniteness challenges under Sections 101 and 112. For patent owners, that means a newly issued patent can face a comprehensive validity attack very early in its life. For petitioners, it offers a powerful chance to shape the dispute before district court litigation fully matures.
The most important issues to watch in this proceeding will be: whether the Board institutes review on all asserted grounds or narrows the petition; how the petitioner frames any Section 101 or Section 112 arguments if included; and how Anagen LLC responds on claim construction, priority, and the sufficiency of the petition’s evidentiary support. PTAB institution decisions in PGRs often provide useful guidance on how the Board is handling broad invalidity theories in the wake of evolving Federal Circuit precedent.
Patent practitioners and in-house IP counsel should follow this case for several reasons. First, PGR filings remain comparatively less common than IPRs, so each new petition can offer meaningful insight into strategy. Second, if the patent involves commercially significant technology, the proceeding may become a roadmap for future challenges to similarly situated patents. Third, the case may provide practical lessons on drafting and defending claims against the full spectrum of PGR attacks.
For ongoing filings, party details, and upcoming PTAB activity, View full case on Docket Alarm.
Understanding the PGR Framework: What Makes PGR2026-00072 Different
Post-grant review, established under the America Invents Act of 2011, is a trial proceeding conducted at the PTAB to review the validity of a patent. Unlike inter partes review, which is limited to prior art patents and printed publications under Sections 102 and 103, PGR opens the door to any invalidity ground under Chapter 10 of Title 35. That includes eligibility under Section 101, written description and enablement under Section 112, and even issues related to double patenting and statutory bar dates. This broader scope makes PGR a uniquely potent tool for petitioners seeking to clear the path for a product or to invalidate a rival’s patent quickly after issuance.
PGR2026-00072 is a case where the full statutory spectrum could be tested. The petition was filed on September 1, 2026, which means the challenged patent must have issued on or after March 16, 2013 (the effective date for first-inventor-to-file provisions). More critically, the patent must not be more than nine months old from its issuance date when the petition is filed — a strict window that forces petitioners to act fast. The fact that this petition has been filed suggests the challenger identified a target patent shortly after issuance and acted decisively to mount a comprehensive attack.
Why PGR Filings Are Less Common but Highly Strategic
Data from the PTAB shows that IPR petitions outnumber PGR petitions by a wide margin, often by more than ten to one. That disparity reflects the procedural constraints: the nine-month window, the higher estoppel consequences in PGR, and the fact that many patents are older than nine months by the time a dispute arises. But when a PGR is filed, it often signals that the petitioner believes the patent is vulnerable on multiple fronts, not just on prior art. It may also indicate that the patent covers subject matter that is borderline under Alice or that the specification lacks adequate support for the breadth of the claims.
For Anagen LLC, being named in a PGR means facing a scrutiny that goes far beyond whether the prior art anticipates. The petitioner can challenge the very foundation of the patent: is the invention even eligible for patent protection? Are the claims indefinite? Does the written description truly support what is claimed? These questions go to the heart of patent quality and can result in cancellation that is much harder to reverse on appeal than a simple obviousness ruling.
What Practitioners Should Watch in PGR2026-00072
The PTAB’s institution decision, expected within three to six months of the petition filing, will be the first major milestone. At that stage, the Board will decide whether to institute trial on some or all grounds. The decision often reveals the Board’s current thinking on difficult legal issues. Given the evolving landscape of patent-eligible subject matter after American Axle & Manufacturing v. Neapco Holdings and subsequent Federal Circuit guidance, any Section 101 challenge in this PGR will be closely watched.
Another critical factor is claim construction. In PGR, the Board applies the Phillips standard (same as in district court), not the broadest reasonable interpretation standard used in IPR for patents that are not expired. That Phillips standard is generally more favorable to patent owners because it gives claims their ordinary and customary meaning in light of the specification. But if the petitioner can demonstrate that the claims are indefinite or lack written description under that standard, that is a powerful argument.
The petitioner’s choice of real parties in interest also matters. If a pharmaceutical or high-tech company is behind the petition, the case could signal a broader industry fight. The docket may eventually reveal this information, but early monitoring is key because the identities can influence settlement dynamics and litigation strategy.
The Role of Evidence and Expert Declarations in a PGR
A PGR petition must be supported by substantial evidence. For Section 101 challenges, that often means expert testimony explaining why the claimed invention is directed to an abstract idea and why the elements do not amount to significantly more. For Section 112 challenges, expert testimony is used to demonstrate that the specification fails to enable a person of ordinary skill to make and use the full scope of the claims, or that the written description does not show possession of the claimed invention. The quality and credibility of these declarations can make or break the institution decision.
In PGR2026-00072, the sufficiency of the evidentiary support will be scrutinized closely by the Board. If the petition relies on weak expert testimony or fails to provide sufficient factual support for its legal conclusions, the Board may deny institution entirely. That outcome would be a significant win for Anagen LLC, as it would effectively immunize the patent from further PGR attacks (subject to appeal).
Strategic Implications for Patent Owners and Petitioners
For patent owners, the filing of a PGR petition is a wake-up call. It means that within a year of issuance, the patent is already under attack on the most comprehensive grounds available. The response strategy requires careful coordination between litigation counsel and PTAB specialists. Anagen LLC will need to consider whether to file a preliminary response, which is optional in PGR, or to wait and see if the Board institutes. A preliminary response can help narrow the issues or even convince the Board to deny institution, but it also reveals the patent owner’s arguments early.
Petitioners, on the other hand, should view PGR as a high-risk, high-reward tool. The estoppel consequences are broader than in IPR: if the PTAB issues a final written decision, the petitioner is estopped from raising any ground it raised or reasonably could have raised in the PGR in district court or at the ITC. That means petitioners must carefully select their grounds and ensure they include all potentially viable challenges. The decision in PGR2026-00072 could become a model for how to manage that risk.
How PGR2026-00072 May Influence Future Filings
Every significant PTAB decision shapes the behavior of litigants. If the institution decision in this case includes a detailed analysis of Section 101 or Section 112 issues, it will provide a reference point for drafting future PGR petitions. Conversely, if the Board denies institution on all grounds, it could signal a more patent-owner-friendly approach at the PTAB for early-stage PGRs. Patent prosecutors and in-house counsel should track this case to understand how the Board is treating broad invalidity theories, especially in light of recent Federal Circuit rulings that have clarified but not settled the law on patent eligibility and enablement.
AEO-Friendly Q&A Section: Common Questions About PGR2026-00072
What is a post-grant review (PGR) and how does it differ from inter partes review (IPR)?
Post-grant review is a trial proceeding at the PTAB that allows any person to challenge the validity of a patent within nine months of its issuance. Unlike IPR, which is limited to prior art patents and printed publications, PGR can raise any invalidity ground under the patent statute, including lack of patent-eligible subject matter under Section 101, lack of written description or enablement under Section 112, and indefiniteness. This broader scope makes PGR a more comprehensive attack, but the filing window is much shorter and estoppel effects are broader.
When was PGR2026-00072 filed, and who is involved?
The petition was filed on September 1, 2026. The docket identifies the matter as Anagen LLC, the patent owner. The petitioner’s identity has not yet been publicly revealed in the early docket, but it will become clear as the case progresses. The case can be tracked via Docket Alarm using the link provided.
What are the key issues to watch in this proceeding?
The most important issues include whether the PTAB institutes review on all asserted grounds, how the petitioner frames any Section 101 or Section 112 challenges, and how Anagen LLC responds on claim construction and evidentiary support. The institution decision will provide early signals about the Board’s current stance on broad invalidity theories.
Why should patent practitioners follow this case even if they are not involved?
Because PGR filings are relatively rare, each new case offers valuable insights into strategy and Board behavior. If the patent covers commercially significant technology, the outcome could affect entire industries. Additionally, the case may provide practical lessons on drafting and defending claims against the full spectrum of PGR attacks, including eligibility and written description challenges.
The Broader PTAB Landscape and the Importance of PGR2026-00072
The PTAB has seen a gradual shift in its approach to discretion and institution decisions. The Fintiv factors, which allow the Board to deny institution when a parallel district court trial is near, are less of a concern in PGRs filed within nine months of issuance because district court litigation is often still early. However, if a district court case has already been filed, the petitioner must be mindful of the Board’s discretion. In PGR2026-00072, the absence of any court filing at this early stage could make institution more likely.
Moreover, the Federal Circuit’s recent decisions on Section 101, particularly in American Axle and Yu v. Apple, have left room for continued debate. The Board has sometimes found claims eligible where the district court found them ineligible, and vice versa. A PGR institution decision that rejects a Section 101 challenge could provide a safe harbor for patent owners, while an institution decision that accepts the challenge could embolden petitioners in other cases.
What the Anagen LLC Patent Might Cover
Without further docket entries, it is impossible to know the technology field of the Anagen LLC patent. However, the name “Anagen LLC” suggests a company that might be involved in biotechnology or medical devices, as “anagen” refers to the growth phase of hair follicles, often used in dermatology and hair restoration. If that is the case, the patent could cover methods of treating hair loss, compositions for stimulating hair growth, or related diagnostic techniques. Such patents often face Section 101 challenges because they may involve natural phenomena or abstract ideas. The PGR could therefore become a test case for how the PTAB treats personalized medicine or treatment method claims under the eligibility framework.
Alternatively, the name could be coincidental, and the patent could be in any field. Regardless, the strategic importance remains. The fact that a petition was filed so quickly after issuance indicates a high level of commercial interest or a prior dispute that was waiting for the patent to issue.
Practical Recommendations for Patent Owners and Challengers
For patent owners like Anagen LLC, the first step is to assemble a PTAB team immediately. The nine-month window for the patent owner to file a preliminary response is short, typically three months from the petition filing date. The response should focus on convincing the Board that the petition fails to establish a reasonable likelihood that at least one claim is unpatentable. Given the breadth of PGR grounds, the patent owner should also prepare claim construction arguments and, if possible, provide expert declarations rebutting the petitioner’s evidence.
For challengers considering a PGR, the lesson from PGR2026-00072 is to move swiftly. The nine-month window is unforgiving. Petitioners must have all prior art and expert evidence ready before the patent issues, and they must be prepared to include every viable ground because estoppel will bar later challenges. Choosing the right expert and ensuring the petition meets the exacting standards of the PTAB is critical.
In-house IP counsel should also monitor PTAB activity in their technology areas. A single PGR filing can signal a shift in enforcement strategy by a competitor. By following PGR2026-00072, they can gain insight into how the Board is handling the intersection of eligibility, enablement, and prior art—issues that arise in nearly every patent portfolio.
The Road Ahead: Timeline and Potential Outcomes
The PTAB typically aims to issue an institution decision within three months of the petition filing, though complex cases may take longer. If instituted, trial will proceed, with a final written decision expected within 12 months of institution. That means a final decision in PGR2026-00072 could come by late 2027 or early 2028. During that time, the parties will engage in discovery, including depositions of expert witnesses, and the Board will hold an oral hearing.
Regardless of the outcome, the case will be appealable to the Federal Circuit. That appeals process can add another one to two years. The entire lifecycle, from petition to final appeal, can take three to four years. For companies operating in fast-moving industries, that timeline can be both a threat and an opportunity. A quick institution decision might force early settlement, while a lengthy trial could allow the patent owner to continue enforcement in the interim.
As the docket for PGR2026-00072 develops, practitioners and analysts should bookmark the case and check for updates. Early access to key documents—the petition, the patent owner’s preliminary response, and the institution decision—will provide the raw material for deeper analysis. The case may end up being cited in dozens of subsequent proceedings if it addresses a novel legal question.
In the end, PGR2026-00072 is more than just another case number. It is a lens through which to understand the current state of PTAB practice, the strategic calculus of patent challengers, and the resilience of recently issued patents in the face of broad-based attacks. Whether you represent a patent owner or a petitioner, this proceeding deserves your attention from the very start.
